KCM
CDMO

Kennedy Capital Management’s Avid Bioservices, Inc. Common Stock CDMO Stock Holding History

Kennedy Capital Management’s Portfolio CDMO Stock Details CDMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-373,397
Closed -$4.25M – 749
2024
Q3 		$4.25M Sell
373,397
-207,840
-36% -$2.09M 0.09% 355
2024
Q2 		$4.15M Sell
581,237
-15,852
-3% -$121K 0.09% 365
2024
Q1 		$4M Buy
597,089
+255,201
+75% +$1.76M 0.08% 374
2023
Q4 		$2.22M Sell
341,888
-16,856
-5% -$109K 0.05% 474
2023
Q3 		$3.39M Sell
358,744
-22,535
-6% -$271K 0.08% 361
2023
Q2 		$5.33M Buy
381,279
+186,850
+96% +$3.19M 0.12% 280
2023
Q1 		$3.65M Buy
194,429
+3,778
+2% +$62.1K 0.11% 314
2022
Q4 		$2.63M Sell
190,651
-82,262
-30% -$1.26M 0.07% 384
2022
Q3 		$5.22M Sell
272,913
-210
-0.1% -$3.83K 0.15% 235
2022
Q2 		$4.17M Buy
273,123
+32,663
+14% +$483K 0.12% 306
2022
Q1 		$4.9M Buy
240,460
+123,409
+105% +$2.51M 0.12% 308
2021
Q4 		$3.42M Sell
117,051
-85,951
-42% -$2.46M 0.07% 396
2021
Q3 		$4.38M Buy
203,002
+27,117
+15% +$655K 0.1% 367
2021
Q2 		$4.51M Sell
175,885
-97,046
-36% -$2.07M 0.1% 374
2021
Q1 		$4.98M Sell
272,931
-149,481
-35% -$2.48M 0.1% 372
2020
Q4 		$4.88M Buy
422,412
+167,601
+66% +$1.53M 0.11% 353
2020
Q3 		$1.94M Sell
254,811
-234,631
-48% -$1.78M 0.06% 488
2020
Q2 		$3.21M Buy
489,442
+198,726
+68% +$1.11M 0.09% 405
2020
Q1 		$1.49M Buy
290,716
+76,955
+36% +$466K 0.05% 506
2019
Q4 		$1.64M Buy
+213,761
New +$1.25M 0.04% 570
2018
Q3 		– Sell
-692,118
Closed -$2.71M – 774
2018
Q2 		$2.71M Sell
692,118
-1,923,244
-74% -$6.67M 0.05% 561
2018
Q1 		$7.64M Buy
+2,615,362
New +$8.08M 0.15% 238
2017
Q4 		– Sell
-69,820
Closed -$219K – 783
2017
Q3 		$219K Sell
69,820
-1,324,246
-95% -$4.97M ﹤0.01% 724
2017
Q2 		$5.93M Buy
1,394,066
+146,867
+12% +$601K 0.11% 322
2017
Q1 		$5.71M Buy
1,247,199
+164,949
+15% +$553K 0.1% 364
2016
Q4 		$2.34M Sell
1,082,250
-37,056
-3% -$86.6K 0.04% 571
2016
Q3 		$3.37M Buy
1,119,306
+33,823
+3% +$90.9K 0.06% 476
2016
Q2 		$2.77M Buy
+1,085,483
New +$3.03M 0.06% 498

Other funds holding CDMO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
AltraVue Capital Bellevue, Washington $1.16B AUM 46.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
PAIM
Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

Kennedy Capital Management's CDMO Position: Q4 2024 in Review

Kennedy Capital Management sold out of Avid Bioservices, Inc. Common Stock (CDMO) in Q4 2024, closing a stake of 373,397 shares — an estimated $4.25M sold.

Kennedy Capital Management first reported a position in CDMO in Q2 2016 and held it in 28 quarters. The position peaked at $7.64M in Q1 2018. 195 funds tracked by Wall St. Rank hold CDMO as of Q4 2024.

  • Kennedy Capital Management reported no remaining Avid Bioservices, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
  • Kennedy Capital Management sold 373,397 Avid Bioservices, Inc. Common Stock shares in Q4 2024, an estimated $4.25M.
  • Kennedy Capital Management first reported a position in Avid Bioservices, Inc. Common Stock in Q2 2016 and held it in 28 quarters.
  • Kennedy Capital Management's Avid Bioservices, Inc. Common Stock position peaked at $7.64M in Q1 2018.
  • 195 funds tracked by Wall St. Rank held Avid Bioservices, Inc. Common Stock as of Q4 2024.

Based on Kennedy Capital Management's 13F filing for Q4 2024, filed 13 Feb 2025.